<s id="wsj_1546.1"> 35
1 	 0 	 N/N 	 1 	 Inc. Amgen
1 	 2 	 (S[dcl]\NP)/S[dcl] 	 1 	 Inc. said
5 	 3 	 NP[nb]/N 	 1 	 earnings its
5 	 4 	 N/N 	 1 	 earnings second-quarter
5 	 6 	 S[dcl]\NP 	 1 	 earnings increased
6 	 2 	 (S[dcl]\NP)/S[dcl] 	 2 	 increased said
6 	 8 	 (((S\NP)\(S\NP))\(S[adj]\NP))/(S[adj]\NP) 	 2 	 increased than
6 	 10 	 ((S\NP)\(S\NP))/NP 	 2 	 increased to
6 	 22 	 ((S\NP)\(S\NP))/NP 	 2 	 increased to
7 	 8 	 (((S\NP)\(S\NP))\(S[adj]\NP))/(S[adj]\NP) 	 3 	 more than
9 	 8 	 (((S\NP)\(S\NP))\(S[adj]\NP))/(S[adj]\NP) 	 4 	 tenfold than
11 	 10 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
13 	 11 	 N/N[num] 	 1 	 million $
13 	 12 	 N/N 	 1 	 million 3.9
17 	 10 	 ((S\NP)\(S\NP))/NP 	 3 	 cents to
17 	 16 	 N/N 	 1 	 cents 22
17 	 18 	 (NP\NP)/N 	 1 	 cents a
19 	 18 	 (NP\NP)/N 	 2 	 share a
22 	 21 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 to due
24 	 22 	 ((S\NP)\(S\NP))/NP 	 3 	 sales to
24 	 23 	 N/N 	 1 	 sales increased
24 	 25 	 (NP\NP)/NP 	 1 	 sales of
27 	 26 	 NP[nb]/N 	 1 	 company the
27 	 28 	 (NP[nb]/N)\NP 	 2 	 company 's
31 	 25 	 (NP\NP)/NP 	 2 	 drug of
31 	 28 	 (NP[nb]/N)\NP 	 1 	 drug 's
31 	 29 	 N/N 	 1 	 drug new
31 	 30 	 N/N 	 1 	 drug antianemia
31 	 32 	 (NP\NP)/NP 	 1 	 drug for
34 	 32 	 (NP\NP)/NP 	 2 	 patients for
34 	 33 	 N/N 	 1 	 patients kidney
<\s>
<s id="wsj_1546.2"> 24
4 	 1 	 (N/N)/(N/N) 	 2 	 Calif.-based Thousand
4 	 2 	 (N/N)/(N/N) 	 2 	 Calif.-based Oaks
6 	 0 	 NP[nb]/N 	 1 	 company The
6 	 4 	 N/N 	 1 	 company Calif.-based
6 	 5 	 N/N 	 1 	 company biotechnology
6 	 7 	 (S[dcl]\NP)/NP 	 1 	 company reported
7 	 18 	 ((S\NP)\(S\NP))/NP 	 2 	 reported for
10 	 9 	 (N/N)/(N/N) 	 2 	 % 97
11 	 7 	 (S[dcl]\NP)/NP 	 2 	 increase reported
11 	 8 	 NP[nb]/N 	 1 	 increase a
11 	 10 	 N/N 	 1 	 increase %
11 	 12 	 (NP\NP)/NP 	 1 	 increase in
11 	 14 	 (NP\NP)/NP 	 1 	 increase to
13 	 12 	 (NP\NP)/NP 	 2 	 revenue in
15 	 14 	 (NP\NP)/NP 	 2 	 $ to
17 	 15 	 N/N[num] 	 1 	 million $
17 	 16 	 N/N 	 1 	 million 42.5
20 	 18 	 ((S\NP)\(S\NP))/NP 	 3 	 quarter for
20 	 19 	 NP[nb]/N 	 1 	 quarter the
20 	 21 	 S[pss]\NP 	 1 	 quarter ended <XB>
21 	 22 	 ((S\NP)\(S\NP))/N[num] 	 2 	 ended Sept.
23 	 22 	 ((S\NP)\(S\NP))/N[num] 	 3 	 30 Sept.
<\s>
<s id="wsj_1546.3"> 25
3 	 0 	 (S/S)/NP 	 2 	 period In
3 	 1 	 NP[nb]/N 	 1 	 period the
3 	 2 	 N/N 	 1 	 period year-ago
5 	 6 	 (S[dcl]\NP)/NP 	 1 	 Amgen reported
6 	 0 	 (S/S)/NP 	 1 	 reported In
8 	 6 	 (S[dcl]\NP)/NP 	 2 	 income reported
8 	 7 	 N/N 	 1 	 income net
8 	 9 	 (NP\NP)/NP 	 1 	 income of
8 	 19 	 (NP\NP)/NP 	 1 	 income on
10 	 9 	 (NP\NP)/NP 	 2 	 $ of
11 	 10 	 N/N[num] 	 1 	 320,000 $
15 	 9 	 (NP\NP)/NP 	 2 	 cents of
15 	 14 	 N/N 	 1 	 cents two
15 	 16 	 (NP\NP)/N 	 1 	 cents a
17 	 16 	 (NP\NP)/N 	 2 	 share a
20 	 19 	 (NP\NP)/NP 	 2 	 revenue on
20 	 21 	 (NP\NP)/NP 	 1 	 revenue of
22 	 21 	 (NP\NP)/NP 	 2 	 $ of
24 	 22 	 N/N[num] 	 1 	 million $
24 	 23 	 N/N 	 1 	 million 21.5
<\s>
<s id="wsj_1546.4"> 38
3 	 0 	 (S/S)/NP 	 2 	 months For
3 	 1 	 NP[nb]/N 	 1 	 months the
3 	 2 	 N/N 	 1 	 months six
6 	 5 	 NP[nb]/N 	 1 	 company the
6 	 7 	 (S[dcl]\NP)/NP 	 1 	 company reported
7 	 0 	 (S/S)/NP 	 1 	 reported For
9 	 10 	 ((N/N)\(S[adj]\NP))/(S[adj]\NP) 	 2 	 more than
11 	 10 	 ((N/N)\(S[adj]\NP))/(S[adj]\NP) 	 3 	 sixfold than
12 	 7 	 (S[dcl]\NP)/NP 	 2 	 increase reported
12 	 8 	 NP[nb]/N 	 1 	 increase a
12 	 10 	 ((N/N)\(S[adj]\NP))/(S[adj]\NP) 	 1 	 increase than
12 	 13 	 (NP\NP)/NP 	 1 	 increase in
12 	 15 	 (NP\NP)/NP 	 1 	 increase to
12 	 26 	 (NP\NP)/NP 	 1 	 increase from
14 	 13 	 (NP\NP)/NP 	 2 	 earnings in
16 	 15 	 (NP\NP)/NP 	 2 	 $ to
18 	 16 	 N/N[num] 	 1 	 million $
18 	 17 	 N/N 	 1 	 million 4.7
22 	 15 	 (NP\NP)/NP 	 2 	 cents to
22 	 21 	 N/N 	 1 	 cents 26
22 	 23 	 (NP\NP)/N 	 1 	 cents a
24 	 23 	 (NP\NP)/N 	 2 	 share a
26 	 37 	 ((NP\NP)\(NP\NP))\NP 	 2 	 from ago
27 	 26 	 (NP\NP)/NP 	 2 	 $ from
28 	 27 	 N/N[num] 	 1 	 625,000 $
32 	 26 	 (NP\NP)/NP 	 2 	 cents from
32 	 31 	 N/N 	 1 	 cents four
32 	 33 	 (NP\NP)/N 	 1 	 cents a
34 	 33 	 (NP\NP)/N 	 2 	 share a
36 	 35 	 NP[nb]/N 	 1 	 year a
36 	 37 	 ((NP\NP)\(NP\NP))\NP 	 3 	 year ago
<\s>
<s id="wsj_1546.5"> 16
0 	 1 	 S[dcl]\NP 	 1 	 Revenue rose
1 	 3 	 (S\NP)\(S\NP) 	 2 	 rose %
1 	 4 	 ((S\NP)\(S\NP))/NP 	 2 	 rose to
1 	 9 	 ((S\NP)\(S\NP))/NP 	 2 	 rose from
3 	 2 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 % 77
5 	 4 	 ((S\NP)\(S\NP))/NP 	 3 	 $ to
7 	 5 	 N/N[num] 	 1 	 million $
7 	 6 	 N/N 	 1 	 million 72.6
11 	 10 	 N/N 	 1 	 year last
11 	 12 	 (NP[nb]/N)\NP 	 2 	 year 's
13 	 9 	 ((S\NP)\(S\NP))/NP 	 3 	 $ from
13 	 12 	 (NP[nb]/N)\NP 	 1 	 $ 's
15 	 13 	 N/N[num] 	 1 	 million $
15 	 14 	 N/N 	 1 	 million 41
<\s>
